The first quarter of 2024 saw a flurry of funding activity in the biotech sector, with early-to-mid-stage companies attracting most of the investment dollars. Among the most notable late-stage deals was blood-based cancer diagnostics firm Freenome‘s $254 million Series E round. The South San Francisco-based company, which is developing a platform for early cancer detection…
Unlearn CEO: Digital twins could slash clinical trial patient enrollment by 25% or more
The startup Unlearn embodies several trendy AI characteristics. Generative AI company? Check. San Francisco headquarters? Check. Aims to disrupt drug development (specifically, clinical trials) with AI? Check. Prominent AI leadership? Check. Mira Murati, the high-profile CTO of OpenAI, joined Unlearn’s board of directors in 2023. But the company’s pedigree is unique. The firm was founded…
NVIDIA expands BioNeMo platform with new foundation models and microservices for AI-powered Drug Discovery
NVIDIA is putting the power of generative AI for drug discovery into the hands of more pharmaceutical and biotech companies with an expanded collection of AI models and flexible deployment options. More than 100 firms are already using the company’s biomolecular BioNeMo platform to accelerate the development of therapeutics. “For the first time in history,…
Microsoft and 1910 Genetics: AI-powered partnership targets billion-dollar savings and growth in drug discovery
The pharmaceutical industry is at a critical juncture: AI and other technological advances offer unprecedented potential, yet the cost of developing new drugs has ballooned for decades, surpassing $2 billion in recent years with the projected return on investment (ROI) falling to a mere 1.2% in 2022, according to Deloitte. Another dimension of the problem…
Pushing the frontier of drug discovery with the world’s most powerful supercomputer
Oak Ridge National Laboratory’s Frontier, the world’s first exascale supercomputer with its dizzying 1.1 exaflop speed, is a game-changer for scientific domains ranging from drug discovery to material science and oceanography. The computer holds the top spot on the TOP500 list, an independent ranking of the world’s most powerful supercomputers. “It’s like having a million…
2024: AI and scientists take turns at the wheel of drug discovery
In drug discovery, interest in harnessing the power of AI ramped up significantly with breakthroughs like AlphaFold, where AI predicted protein structures with astounding accuracy. AI’s initial focus was analyzing existing data, with machine learning systems excelling at tasks like predicting new drug interactions, molecular behaviors, and even biological pathways, based on troves of experimental…
Big Pharma clicks soared, but new cell therapies made you buzz: What drove biopharma interest in 2023?
Despite biopharma’s 2023 layoffs and challenges, innovation won your clicks last year with over 130,000 of them on our Pharma 50 report alone. But while giants dominated, your clicks showed disruptive tech wasn’t far behind. The next-most popular article was a roundup of 100 trailblazing cell and gene therapy companies with more than 80,000 views.…
Skynet with benefits: Can AI and humans become a drug discovery superorganism?
Will the credit for future mega-blockbuster drugs, in some cases, go to a carefully-programmed AI discovery system connected to a “self-driving lab” that verified its potential? Certainly, AI is hyped, but so are potential profits of potentially AI-optimized drugs. The exploding volumes of scientific data highlight a shift often overlooked: what does “inventor” even mean when…
Unifying disparate data in clinical trial management with advanced data technology
The increasing complexities in clinical trials, including expanded patient populations, decentralized trials and new technologies, are directly impacting the amount of data and information available to clinical trial sponsors. Though this provides significant value to the industry, it presents a new challenge of consolidating disparate and siloed systems, improving standardization and unifying the explosion of…
Bridging the gap: How resource sheets translate complex clinical trial data into patient empowerment
As patients take a more active role in managing their health, they can find navigating the complexities of clinical trial results daunting. Having access to clear, accurate information is crucial for informed decision-making. This is where patient-reported data from clinical trials has real value, offering key insights into the real world experiences of participants, both…
Alliance with Google Cloud the latest to help Atropos Health bridge the evidence gap in medicine
The Stanford spinout Atropos Health, which taps real-world data to analyze patient outcomes, disease trajectories, treatment effectiveness, is joining forces with Google Cloud. The company had already forged an alliance with AWS to offer its real-world evidence offerings on the AWS Marketplace and join the AWS Partner Network. The company’s core aim is to give…
How digital pathology can transform the value of clinical trial information
The field of pathology is gradually going digital, marking a pronounced shift from the traditional use of glass slides, a practice that dates back to the Victorian era. Digital pathology uptake reached an “exponential” pace in the wake of the pandemic, noted Dr. Monika Lamba Saini, pathologist-scientist, director of digital innovation at Q2 Solutions, an…
Inside Amgen’s ATOMIC strategy to use ML to accelerate clinical trials
Amgen has developed a machine learning platform to slash clinical trial times through smarter site selection. Known as ATOMIC, short for Analytical Trial Optimization Module, the system crunches disparate datasets to predict optimal trial locations, expedite enrollment and trial processes. Early results indicate more than a two times increase in enrollment speed at ATOMIC sites.…
Supercomputer-based Bayesian approach to AI pays dividends for BPGbio
In an AI hype-filled biopharma industry, one company is taking a back-to-basics yet supercomputer-powered approach — using Bayesian analysis on massive patient datasets to guide drug discovery. The company crunches trillions of data points per patient. “It’s massive, which is why we use a supercomputer,” said Niven R. Narain, Ph.D., BPGbio CEO. The company has…
Moving beyond buzzwords: When will a rising AI tide lift all Big Pharma boats?
For all of the talk about AI in drug discovery and development, few Big Pharmas are putting up big bucks in AI spending. A CRB survey from late 2023 painted a conservative picture: about half of drug developers planned on allocating between $1 and $10 million for data and AI projects over the next two…
Could an ‘extreme’ hibernating ground squirrel unlock new obesity treatments?
In late 2023, Eli Lilly, whose stock is now up close to 80% over the past year, inked a deal with the Emeryville, California–based Fauna Bio potentially worth $494 million that focuses on the discovery of novel drug targets for treating obesity. In 2020, Fauna entered into an obesity-focused collaboration with Novo Nordisk, Lilly’s primary…
Antibody-drug conjugates, genomics, and more: Key trends at the JP Morgan Healthcare Conference
The 2024 JPMorgan Healthcare Conference showcased the resilience and innovation driving the biotech sector, even as the sector has recently grappled with financial headwinds such as declining IPOs, layoffs, and tightening cash reserves. Companies are tightening operations while still pushing forward in developing novel technologies like machine learning for drug discovery, cell and gene therapies,…
Quantum promises a bright future for the pharma industry
Quantum computing technology continues to advance closer to an everyday reality. While the potential applications of quantum in certain sectors are more speculative, the pharmaceutical industry is poised to be transformed by quantum technology.This sector is likely to be the fastest to unlock the benefits of quantum computing, once the technology is fully realized. But…
Recursion partners with NVIDIA to unveil Phenom-Beta, democratizing access to its $1 Billion phenomics investment
In sync with the JP Morgan Health Care Conference, Recursion Pharmaceuticals has unveiled Phenom-Beta, a deep learning model designed to transform cell microscopy images into meaningful biological representations. “Phenom-Beta allows you to take images of human cells from a microscope or other sources and turn them into mathematical representations of biology,” said Chris Gibson, CEO…
Wrangling medical imaging data: Strategies to streamline AI-powered workflows
The value of artificial intelligence (AI) and machine learning (ML) in medical imaging is undeniable: more accurate diagnoses, predictive insights and streamlined workflows. However, as Big Pharma and medical research institutions amplify their AI and ML endeavors, they confront pivotal challenges. Chief among these challenges are the intricacies of labeling and annotating medical images. Approximately…
ConcertAI acquisition will boost CancerLinQ data capabilities with AI focus
The AI oncology startup ConcertAI recently acquired CancerLinQ, one of the largest oncology real-world data and quality of care technology service entities. Originally developed by the American Society of Clinical Oncology (ASCO) in 2013, CancerLinQ aims to use real-world data and technology to improve cancer care and advance evidence-based research. CancerLinQ has developed one of…
Unlocking generative AI requires reshaping culture, operations, and talent dynamics
In drug discovery and development, generative AI and natural-language processing (NLP) tools promise more than incremental productivity gains. For companies that can integrate such tools strategically into their workflows, the tools open the door to a fundamental rethinking of operational processes. For instance, generative AI tools can accelerate drafting of research articles, novel target identification,…
AWS-NVIDIA gen-AI alliance epitomizes Big Tech’s growing interest in drug discovery
The allure of healthcare has long captivated Big Tech giants. Over the past fifteen years or so, several prominent companies in the sector have ventured into the life sciences sector with ambitious projects, only to often find themselves retreating. The dynamic appears to be changing, particularly in drug discovery, thanks in part to burgeoning data…
At AWS re:Invent, Pfizer exec frames digital as a core business strategy
In the midst of a global pandemic, Pfizer, under the leadership of its chief digital and technology officer Lidia Fonseca, achieved what was once thought impossible. The company, with the partnership of BioNTech, developed a COVID-19 vaccine in only 269 days, a process that traditionally would have taken 8 to 10 years. While prior research…
2024 forecast: Navigating new frontiers in pharma with AI, synthetic data, and strategic partnerships
In late 2022, we published a series of predictions, which, among other things, projected that 2023 would be a “massive showcase” for machine learning (ML) in drug discovery and development. And in many ways, 2023 was a pivotal year for AI in pharma. This evolution in AI and ML applications in pharma built upon the…